Beam Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Highlights Expense Discipline BioAge Labs Q1 2026 Earnings EPS Beat on Lower Loss PreRevenue Stage Continues Central Garden Pet CENT Q1 2026 Earnings Strong EPS Beat of 154 Drives Modest Stock Gains Gain Therapeutics Inc GANX Q1 2026 Earnings Narrower Loss Surpasses Estimates Stock Edges Higher VNDA Q1 2026 Earnings EPS Misses Estimates as Losses Widen Stock Slides MaxCyte Q1 2026 Earnings EPS Beat Highlights Operational Cost Discipline Amid Revenue Disclosure Gaps